Home › Non-Small Cell Lung Cancer › Indiana
Non-Small Cell Lung Cancer clinical trials in Indiana
49 studies for Non-Small Cell Lung Cancer are looking for participants at sites in Indiana.
Cities in Indiana
- Indianapolis32 studies
- Fort Wayne17 studies
- Hammond11 studies
- South Bend5 studies
- Gary4 studies
- Evansville3 studies
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Northwest Cancer Centers, P.C., Dyer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07361510Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Northwest Cancer Center - Crown Point, Crown Point
- Northwest Oncology LLC, Dyer
- Parkview Regional Medical Center, Fort Wayne
- and 7 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT04267848A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07361497Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Northwest Cancer Center - Crown Point, Crown Point
- Northwest Oncology LLC, Dyer
- Saint Mary Medical Center, Hobart
- and 4 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07388524Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Parkview Comprehensive Cancer Center /ID# 271879, Fort Wayne
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06772623Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- IU Health West Hospital, Avon
- IU Health North Hospital, Carmel
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06498635A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Indiana University Health Arnett Cancer Center ( Site 0116), Lafayette
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07190248A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Franciscan Health ( Site 0219), Indianapolis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06623422Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Community Health Network, Inc, Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07222566A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Franciscan Health, Munster
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07154290A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
- Investigative Clinical Research of Indiana, LLC, Noblesville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06667076A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Parkview Research Center /ID# 277651, Fort Wayne
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07155187A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Parkview Research Center at Parkview Regional Medical Center ( Site 0089), Fort Wayne
- Indiana University Health Arnett Cancer Center ( Site 0076), Lafayette
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06312137Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Parkview Research Center at Parkview Regional Medical Center, Fort Wayne
- Franciscan Health, Indianapolis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06890598Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Noblesville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06357533Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Community Health Network, Indianapolis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne
- Indiana University Health University Hospital, Indianapolis
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06712316A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Northwest Cancer Centers, P.C., Dyer
- Parkview Research Center at Parkview Regional Medical Center, Fort Wayne
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06875310A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Indiana University (IU) Health - Multi-D Oncology Clinic, Indianapolis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07488676A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Fort Wayne
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06692738Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Indianapolis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06767514Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Goshen Center for Cancer Care, Goshen
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT04613596Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07761910Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06625775A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Parkview Research Center at Parkview Regional Medical Center, Fort Wayne
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
- Franciscan Health, Indianapolis
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06119581A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- IU Simon Cancer Center, Indianapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06465069A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
- Community Health Network, Indianapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT07027514Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Research Site, Fort Wayne
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT06350097MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- Community Health Network, Indianapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT06586515Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #4, Indianapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT05176483A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 28, 2026 · NCT06150664A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- UChicago Medicine - Northwest Indiana, Crown Point
- Fort Wayne Medical Oncology and Hematology, Inc, Fort Wayne
- Community Health Network, Inc, Indianapolis
- and 3 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 6, 2026 · NCT04389632LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- Parkview Packnett Family Cancer Institute, Fort Wayne
- Franciscan Health Indianapolis, Indianapolis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jun 25, 2026 · NCT06216301A Study of LY4175408 in Participants With Advanced Cancer
- Community Health Network, Indianapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT07046923Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593, Fort Wayne
- Community Health Network, Inc. /ID# 243011, Indianapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT05005403Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT06116682Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 5, 2026 · NCT04317534Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated May 5, 2026 · NCT06616584Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
RecruitingPhase 2
18 Minutes · All sexes · Updated May 5, 2026 · NCT06031688A Study of VET3-TGI in Patients With Solid Tumors
- Community Health Network, Indianapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 7, 2026 · NCT06444815From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.